Fc Effector Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of Action
Poster Sep 19, 2017
Zhi-jie Jey Cheng, Rich Moravec, Aileen Paguio, Denise Garvin, Frank Fan, and Mei Cong
Drug developers and regulatory authorities recognize antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) as important mechanisms of action (MOA) of therapeutic antibodies. Traditional ADCC and ADCP bioassays use primary cells, which are labor intensive and highly variable. Less variable, easy-to-use and consistent analysis of these important MOA is needed in drug development programs.
To meet this need, we have developed a suite of functional cell-based Fc Effector reporter bioassays for the following receptors:
• Human FcgRIIIa (V158 and F158 variants)
• Human FcgRIIa (H131 and R131 variants)
• Human FcgRI
• Mouse FcgRIV* & FcgRIII*
Each bioassay is provided in “thaw-and-use” format for a rapid and convenient workflow and further reduction in assay variability. In qualification studies according to ICH guidelines, the bioassays show specificity, accuracy, precision, and linearity enabling their use in antibody screening, characterization, stability and potency studies.
Histone Deacetylase 6 (HDAC6) As A Therapeutic Target in Chronic Lymphocytic LeukemiaPoster
This study investigates the role of histone deacetylase 6 (HDAC6) in chronic lymphocytic leukemia and establishes it as a novel therapeutic target for the treatment of this disease.READ MORE
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell ImmunotherapiesPoster
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.READ MORE
Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint ImmunotherapyPoster
Cell-based reporter bioassays overcome the limitations of primary cell-based assays for functional characterization of antibody and other biologics drugs targeting individual or combination immune checkpoint receptors. Here we show a portfolio of immune inhibitory checkpoint bioassays targeting PD-1/PD-L1, TIGIT/CD155, CTLA4/CD80/86 and LAG3/MHCII, that can be used for antibody screening, characterization, potency and stability studies.READ MORE